Regenxbio (RGNX) news
Recent news
Regenxbio Inc.: Mizuho initiates coverage with outperform rating; target price $22.00
Mizuho Securities has initiated coverage of Regenxbio Inc. (RGNX) with an "Outperform" rating and a target price of $22.00 , signaling confidence in the company’s growth potential and strategic direction. This move aligns with broader analyst activity in the biotechnology sector, where several…
AInvest Wire · Oct 5, 2026Regenxbio presents positive three-year durability data for Surabgene lomparovvec in diabetic retinopathy at retina
Regenxbio Inc. (NASDAQ: RGNX) recently presented positive three-year durability data for its gene therapy, surabgene lomparvovec, in the treatment of diabetic retinopathy at the Retina meeting. The long-term clinical trial results indicate sustained efficacy and a reduced treatment burden, with the…
AInvest Wire · Sep 24, 2026Regenxbio - Agrees not to sue Sarepta or affiliates over existing Elevidys or AAVrh74-based capsids - SEC filing
Regenxbio Inc. has agreed not to pursue legal action against Sarepta Therapeutics or its affiliates regarding the use of existing Elevidys or AAVrh74-based capsids, according to a recent SEC filing [1]. This agreement appears to resolve potential intellectual property disputes related to gene…
AInvest Wire · Sep 23, 2026Regenxbio - All ongoing patent litigation regarding patents-in-suit to be terminated with prejudice - SEC filing
Regenxbio Inc. has announced that all ongoing patent litigation involving the patents-in-suit will be terminated with prejudice, as disclosed in a recent SEC filing [1]. This development marks a significant resolution to the legal disputes that had previously raised concerns among investors and…
AInvest Wire · Sep 23, 2026Regenxbio - Sarepta to pay $39 mln to Regenxbio within 10 days of effective date - SEC filing
According to a recent SEC filing, Sarepta Therapeutics has agreed to pay Regenxbio $39 million within 10 days . The payment is part of a legal resolution between the two biotechnology firms, which has been formalized in a public filing with the U.S. Securities and Exchange Commission. The terms of…
AInvest Wire · Sep 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.